News By Tag
News By Location
Follow on Google News
Global Albumin Market is expected to grow at a healthy CAGR of ~6% by 2026
Albumin is the most abundant circulating protein in the plasma, accounting for more than half of the human plasma protein.
The Global Albumin Market is expected to grow at a rate of ~6% by 2026. The development of albumin-based nanoparticles for drug delivery, high demand for albumin in R&D activities & clinical trials, rising production of immunoglobulin, growing plasma collection, increased preference for recombinant albumin in drug delivery, increasing awareness about the benefits of albumin, growing usage of albumin as blood volumizer in a condition of shocks & burns, and rise in non-therapeutic applications of albumin as a multifunctional excipient are some of the key factors driving the global albumin market.
Growing Demand for Albumin in Research & Development and Clinical Trials Drives the Global Albumin Market
Malignant, inflammatory, metabolic, and viral diseases are specifically treated and diagnosed with albumin-based therapeutic agents. Considering the commercial success of products that utilise albumin as a drug carrier and the ongoing clinical trials albumin is attracting the interest of researchers, pharmaceutical, and biotechnological companies.
Albumin-Based Nanoparticles Offer Promising Drug Delivery System for Cancer Treatment
Albumin is a versatile biomaterial for the synthesis of nanoparticles. The efficiency of the albumin-based delivery resides in its capacity to improve tumor targeting and accumulation. Additionally, albumin can bind to special receptors overexpressed on cancer cells and enhance nanoparticle binding and internalization.
Explore Premium Report on Albumin Market @ https://meditechinsights.com/
Growing Adoption of Recombinant Albumin over Serum-based Albumin for Drug Delivery Fuels the Albumin Market Demand
As regulatory guidelines have driven the need for animal-free options, there has been a decline in the use of serum-derived albumin. Historical risks related to human serum albumin have been eliminated with the availability of recombinant albumin. It also provides a relatively simple solution to traditional formulation strategies and provides a cost-effective, single solution to several stability issues.
Key Challenges/ Constraints:
The stringent government regulations, limited reimbursement, rising shift towards serum-free solutions, and side effects associated with the use of albumin are the major factors restraining the growth of the albumin market.
+ 32 498 86 80 79
Account Email Address Account Phone Number Disclaimer Report Abuse